Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia

被引：79

作者：

Au, WY

Kumana, CR

Kou, M

Mak, R

Chan, GCF

Lam, CW

Kwong, YL

机构：

[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China

[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China

来源：

BLOOD | 2003年 / 102卷 / 01期

关键词：

D O I：

10.1182/blood-2003-01-0298

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：407 / 408

页数：2

共 10 条

[1] Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide [J].

Au, WY ;

Chim, CS ;

Lie, AKW ;

Liang, R ;

Kwong, YL .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) :130-132

[2] Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide [J].

Camacho, LH ;

Soignet, SL ;

Chanel, S ;

Ho, R ;

Heller, G ;

Scheinberg, DA ;

Ellison, R ;

Warrell, RP .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (13) :2620-2625

[3] Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies [J].

Kumana, CR ;

Au, WY ;

Lee, NSL ;

Kou, M ;

Mak, RWM ;

Lam, CW ;

Kwong, YL .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (08) :521-526

[4] Delicious poison: Arsenic trioxide for the treatment of leukemia [J].

Kwong, YL ;

Todd, D .

BLOOD, 1997, 89 (09) :3487-3488

[5] Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot study [J].

Kwong, YL ;

Au, WY ;

Chim, CS ;

Pang, A ;

Suen, C ;

Liang, R .

AMERICAN JOURNAL OF HEMATOLOGY, 2001, 66 (04) :274-279

[6] Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report [J].

Lu, DP ;

Qiu, JY ;

Jiang, B ;

Wang, Q ;

Liu, KY ;

Liu, YR ;

Chen, SS .

BLOOD, 2002, 99 (09) :3136-3143

[7] Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients [J].

Niu, C ;

Yan, H ;

Yu, T ;

Sun, HP ;

Liu, JX ;

Li, XS ;

Wu, W ;

Zhang, FQ ;

Chen, Y ;

Zhou, L ;

Li, JM ;

Zeng, XY ;

Yang, RRO ;

Yuan, MM ;

Ren, MY ;

Gu, FY ;

Cao, Q ;

Gu, BW ;

Su, XY ;

Chen, GQ ;

Xiong, SM ;

Zhang, TD ;

Waxman, S ;

Wang, ZY ;

Chen, Z ;

Hu, J ;

Shen, ZX ;

Chen, SJ .

BLOOD, 1999, 94 (10) :3315-3324

[8] Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia [J].

Ohnishi, K ;

Yoshida, H ;

Shigeno, K ;

Nakamura, S ;

Fujisawa, S ;

Naito, K ;

Shinjo, K ;

Fujita, Y ;

Matsui, H ;

Takeshita, A ;

Sugiyama, S ;

Satoh, H ;

Terada, H ;

Ohno, R .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (11) :881-885

[9] United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia [J].

Soignet, SL ;

Frankel, SR ;

Douer, D ;

Tallman, MS ;

Kantarjian, H ;

Calleja, E ;

Stone, RM ;

Kalaycio, M ;

Scheinberg, DA ;

Steinherz, P ;

Sievers, EL ;

Coutré, S ;

Dahlberg, S ;

Ellison, R ;

Warrell, RP .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3852-3860

[10] Acute promyelocytic leukemia: evolving therapeutic strategies [J].

Tallman, MS ;

Nabhan, C ;

Feusner, JH ;

Rowe, JM .

BLOOD, 2002, 99 (03) :759-767

← 1 →